TEK

Overview

TEK (TIE2) encodes a receptor tyrosine kinase expressed predominantly on endothelial cells that regulates vascular development, angiogenesis, and vascular stability through angiopoietin ligands. It is included in the multi-kinase inhibitor target profile investigated in nasopharyngeal carcinoma (NPC).

Alterations observed in the corpus

  • TEK is listed among genes targeted by multi-kinase inhibitors under investigation in recurrent/metastatic NPC. PMID:24952746
  • Low-frequency but FDA-druggable alteration in the RTK pathway in hepatocellular carcinoma (1% FDA-targetable); part of the 28% druggable-alteration landscape in HCC. PMID:25822088

Cancer types (linked)

  • NPC – TEK is a component of the multi-kinase inhibitor target profile in R/M NPC alongside VEGFR2 (KDR), RET, FLT3, and others. PMID:24952746

Co-occurrence and mutual exclusivity

  • No co-occurrence or mutual exclusivity data reported in the current corpus.

Therapeutic relevance

  • Multi-kinase TKIs inhibiting TEK (e.g., cabozantinib) are being investigated in NPC primarily as anti-angiogenic agents; TEK-alteration-selected strategies are not reported. PMID:24952746

Open questions

  • TEK mutation frequency in NPC and whether TEK alterations predict TKI response are uncharacterized in the current corpus.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:25822088

This page was processed by crosslinker on 2026-05-14.